Drugs / Human CMV pp65-LAMP mRNA-pulsed autologous DCs
Human CMV pp65-LAMP mRNA-pulsed autologous DCs
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03688178 | Aug 2020 → Mar 2027 expected | glioblastoma | Annick Desjardins, MD | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03927222 | Sep 2019 → Feb 2023 | glioblastoma | Mustafa Khasraw, MBChB, MD, FRCP, FRACP | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Human CMV pp65-LAMP mRNA-pulsed autologous DCs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03688178 ↗ |
| Modality | Cell therapy | “autologous DCs” NCT03927222 ↗ |
| Route | Other | “2x10\^7 human CMV pp65-LAMP mRNA-pulsed autologous DCs are given intradermally and bilaterally at the groin site” NCT03688178 ↗ |